| Features: |
| Recombinant TRAIL - Recombinant Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Recommended Abbreviation: rTRAIL Alternative Names: Recombinant TRAIL, recombinant TNFSF10, Apo2L/TRAIL Type: Recombinant protein / biologic anticancer agent / death-receptor agonist Function: Recombinant TRAIL binds primarily to the death receptors DR4 (TNFRSF10A) and DR5 (TNFRSF10B), causing death-inducing signaling complex formation, caspase-8 activation, downstream caspase activation, and apoptosis. Many cancer cells are more sensitive to TRAIL-induced apoptosis than normal cells, although resistance is common. Cancer: ↑ TRAIL-induced death-receptor signaling is generally favorable because it promotes extrinsic apoptosis in susceptible cancer cells. Recombinant TRAIL and TRAIL-receptor agonists have shown substantial preclinical anticancer activity, although clinical efficacy has been limited by short circulating half-life, receptor biology, and intrinsic or acquired TRAIL resistance. |
| Source: |
| Type: protein |
| c-FLIP (cellular FLICE-like inhibitory protein) also know as FLIP - is a protein that plays a crucial role in the regulation of apoptosis, or programmed cell death. It is a key regulator of the extrinsic pathway of apoptosis, which is mediated by death receptors such as Fas and TNF-R1. c-FLIP is a pseudokinase that can inhibit the activation of caspase-8, a key enzyme in the extrinsic pathway of apoptosis. By inhibiting caspase-8 activation, c-FLIP can prevent the initiation of the apoptotic cascade and promote cell survival. In cancer, c-FLIP is often overexpressed, which can contribute to the development and progression of the disease. |
| 8152- | lamb, | TRAIL/rTRAIL, | Lambertianic Acid Sensitizes Non-Small Cell Lung Cancers to TRAIL-Induced Apoptosis via Inhibition of XIAP/NF-κB and Activation of Caspases and Death Receptor 4 |
| - | in-vitro, | NSCLC, | A549 | - | in-vitro, | Lung, | H1299 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:474 Target#:885 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid